Benzinga | Sep 20, 2021 08:35AM EDT

Gilead To Present Latest Antiviral Research Data Addressing Urgent Global Needs In Infectious Disease At IDWeek 2021

Gilead Sciences, Inc. (NASDAQ:GILD) today announced the upcoming presentation of new data from the company's virology research and development programs at the virtual IDWeek 2021 conference, taking place September 29 -- October 3. The findings in COVID-19 research, HIV treatment research and HIV prevention research are the latest example of Gilead's ongoing commitment to help address the evolving COVID-19 pandemic and the needs of people affected by HIV.

"In partnership with the infectious disease community, we continue to monitor and respond to the devastating global viral pandemic, while simultaneously working to maintain the tremendous progress that has been made toward ending the HIV epidemic," said Frank Duff, MD, Senior Vice President, Virology Therapeutic Area Head, Gilead Sciences. "Our antiviral research program is not only expanding the scientific understanding of our current HIV and COVID-19 medicines, it also urgently pursues innovation to address the dynamic nature of these pandemics and evolving needs of the communities most impacted."